Publications by authors named "S Wakita"
Neural Basis of Perceptual Surface Qualities and Materials: Evidence from EEG Decoding.
J Cogn Neurosci
November 2024
Article Synopsis
- The study investigates how the human brain perceives material properties like glossiness and smoothness using visual evoked potentials (VEPs) from images of various materials.
- The results show that material categories and surface properties can be accurately classified from VEPs within 150 to 200 milliseconds after visual stimulus presentation.
- Additionally, deep learning models demonstrated that surface images reconstructed from VEPs closely matched the original images in terms of perceived material categories and properties, suggesting early neural responses are important for material perception.
We report the first large-scale retrospective cohort study on adolescent and young adult (AYA) polycythemia vera (PV) and essential thrombocythemia (ET) in Japan, a subgroup analysis using Japanese multicenter registry data (JSH-MPN-R18). This study included patients with PV (n = 31) or ET (n = 141) aged 20 to 39 years at the initial visit. Hemorrhage-free survival (HFS) was better in AYA ET than in non-AYA ET (5-year HFS: 100% vs.
View Article and Find Full Text PDFFMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML) has a poor prognosis, particularly with DNMT3A and NPM1 mutations. Quizartinib, a FLT3 inhibitor showing clinical benefit in FLT3-ITD-positive AML, has unclear safety and efficacy when combined with donor lymphocyte infusion (DLI). We report a case of FLT3-ITD-positive AML with DNMT3A and NPM1 mutations that relapsed after allogeneic hematopoietic stem cell transplantation (allo-HCT) and was treated with quizartinib and DLI.
View Article and Find Full Text PDFMixed-phenotype acute leukemia (MPAL) with -TKD mutations is a rare and challenging subtype of leukemia. Effective management strategies are crucial for improving patient outcomes. A 31-year-old man with -TKD-mutated MPAL achieved hematological remission through the JALSG ALL202-O protocol and gilteritinib, followed by cord blood transplantation (CBT).
View Article and Find Full Text PDF